Researchers find hundreds of clinics marketing selling stem cell interventions in US

02 Jul 2016

1

Contrary to popular perception, about experimental medical procedures being conducted in countries where lawlessness or lax supervision prevailed, two researchers have found 351 businesses selling stem cell interventions from 570 American-based clinics.

The researchers conducted a keyword-based internet search and analysis.

The businesses marketed which directly to consumers and in some cases to desperate patients in failing health often advertised types of stem cell treatments that did to fit the Food and Drug Administration's (FDA) regulations.

"When you go on the Internet, what comes up, the first thing you see are these businesses," said Leigh Turner, co-author of the study. He added that many sites appear to intentionally blur the distinctions between approved, evidence-based scientific practices and quack procedures, edition.cnn.com reported. "The websites are well-done, with links to scientific studies and patient testimonials."

"It's a jungle out there," said Paul Knoepfler, co-author of the study and a stem cell scientist, adding that some treatment centers will call what they're doing "a clinical trial" when it's nothing of the sort. Instead, it's simply a for-profit center administering experimental procedures to earn income. "In college, I had friends participating in experimental trials, and they got paid," he said.

Such clinics could offer dangerous, often exorbitantly priced ''treatments.'' Their targets were usually the vulnerable and desperate, including terminal cancer patients, parents of autistic children, and grown children of parents with Alzheimer's or Parkinson's disease.

''Our analysis should serve as a valuable resource for contemporary debate concerning whether the US marketplace for stem cell interventions is adequately monitored and regulated by the FDA, the Federal Trade Commission, state medical boards, and other agencies tasked with promoting patient safety and accurate advertising,'' the authors conclude.

Latest articles

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

Toyota set for third straight quarterly profit drop as costs and tariffs weigh

Toyota set for third straight quarterly profit drop as costs and tariffs weigh